The global clinical next-generation sequencing (NGS) market, valued at USD 6.2 billion in 2024, is expected to reach USD 15.2 billion by 2032 with a ...

Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 7.4% in the afternoon session after the ...

Now that PacBio has broken through the $1 level that avoids Nasdaq delisting for now, we can focus on what might be ahead: ...

Complex regions of the human genome remained uncharted, even after researchers sequenced the genome in its entirety. That is, ...

Researchers have decoded the chromosome-level genome of Houttuynia cordata, an important East Asian medicinal plant known for its strong flavor and ...

Three-in-one system integrates large fragment analytics, DNA size selection and fluorometric quantification for long-read ...

Overview of Genomics in Cancer Care MarketThe global Genomics in Cancer Care Market is valued at USD 24.5 Billion in 2024 and ...

PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset macroeconomic concerns and drive 2025 growth.

The Ngāi Tahu Research Centre has entered into a strategic partnership with de-extinction company, Colossal Biosciences, and Sir Peter Jackson, to resurrect the South Island Giant Moa and other Taonga ...

Pacific Biosciences of California (NASDAQ:PACB) is a biotech company that focuses on advanced genomic technologies, such as whole-genome sequencing, target sequencing, RNA sequencing, and ...

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Earnings Call Transcript February 13, 2025 Pacific Biosciences of California, Inc. beats earnings expectations. Reported EPS is $0.51 ...